Unum Therapeutics Inc (NASDAQ:UMRX) insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $8.46, for a total value of $97,163.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Seth Ettenberg also recently made the following trade(s):
- On Tuesday, September 25th, Seth Ettenberg sold 11,485 shares of Unum Therapeutics stock. The shares were sold at an average price of $12.47, for a total value of $143,217.95.
Shares of UMRX stock traded up $0.03 during trading hours on Thursday, hitting $7.47. The stock had a trading volume of 101,022 shares, compared to its average volume of 224,733. Unum Therapeutics Inc has a one year low of $6.75 and a one year high of $17.66.
Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings data on Monday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative return on equity of 382.71% and a negative net margin of 404.34%. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.29 million. As a group, analysts predict that Unum Therapeutics Inc will post -1.56 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Spark Investment Management LLC purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $186,000. Wasatch Advisors Inc. boosted its position in shares of Unum Therapeutics by 5.3% during the second quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock valued at $3,840,000 after buying an additional 13,525 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $177,000. Cowen Inc. purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $8,341,000. Finally, BlackRock Inc. purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $6,403,000. 51.81% of the stock is currently owned by institutional investors.
UMRX has been the topic of several research analyst reports. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research report on Monday. Zacks Investment Research upgraded Unum Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. Morgan Stanley lifted their target price on Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Finally, Wedbush lifted their target price on Unum Therapeutics from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Unum Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.67.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.